Biotech2 years ago
Laminar Pharma Expects to Reach €1 Billion in 2026 and Rules Out IPO
In addition to the drug against brain tumors, Laminar has two other drugs licensed in phase two: one, developed together with Ability Pharma, against pancreatic cancer,...